Hims & Hers Health, Inc. (HIMS)
| Market Cap | 10.92B |
| Revenue (ttm) | 2.01B |
| Net Income (ttm) | 193.60M |
| Shares Out | 226.02M |
| EPS (ttm) | 0.79 |
| PE Ratio | 61.27 |
| Forward PE | 63.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,268,209 |
| Open | 48.59 |
| Previous Close | 47.96 |
| Day's Range | 46.76 - 48.65 |
| 52-Week Range | 13.47 - 72.98 |
| Beta | 2.09 |
| Analysts | Hold |
| Price Target | 38.30 (-20.75%) |
| Earnings Date | Aug 4, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $38.3, which is a decrease of -20.75% from the latest price.
News
Hims & Hers CEO sells $33 million in stock after a massive rally
The company says the sales came from indirect holdings and were for “tax and philanthropic purposes.”
Why is Novo Nordisk excluding Hims & Hers in its lawsuits over Wegovy copies?
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers. The high-profil...
As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims?
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers.
Hims & Hers: A High-Risk Bet
Upgrading Hims & Hers Health, Inc. to a speculative Buy after a 20% post-earnings selloff, given management's reaffirmed guidance and near-term demand for personalized compounded GLP-1s. I believe the...
Hims & Hers: From Telehealth To Wellness Hub, The Bright Future
I remain bullish on Hims & Hers Health, viewing the recent price dip as a buying opportunity given its strong long-term prospects. Technological innovation and personalized care, including at-home lab...
Hims & Hers: Still Growing After Breakup With Novo Nordisk
Hims & Hers is positioned as a leading telehealth platform targeting millennial and Gen Z consumers with affordable, accessible healthcare solutions. The company's strong revenue growth, expanding pro...
Hims & Hers: GLP-1 Strategy Is On Dubious Grounds
Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. The results reflect GLP-1 concerns. Hims & Hers' GLP-1 strategy is now on dubious grounds after Novo Nor...
Wait Out The GLP-1 Storm - Buy The Hims And Hers Post-Earnings Dip
Hims and Hers faced a short-term revenue dip due to regulatory changes and GLP-1 customer offboarding, but core growth remains strong. Subscriber numbers surged 31% quarter-over-quarter, and product d...
Weighing HIMS GLP-1 Trends, NVO Partnership & Other Businesses
Michael Cherny sees opportunity for Hims & Hers (HIMS), as long as it can overcome headwinds facing its non-weight loss businesses. He argues the stock hasn't traded on fundamentals and weighs heavily...
Hims & Hers drops on revenue miss
CNBC's Brandon Gomez joins 'Squawk on the Street' to discuss the latest earnings from Hims & Hers.
Hims & Hers Health Posts Weak Q2; Heading Into More Near-Term Challenges, Analysts Say
Shares of Hims & Hers Health Inc HIMS are under pressure Tuesday, after the company reported downbeat second-quarter revenues.
Hims & Hers falls as declining subscriber base weighs on revenue
Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment a...
MSFT & META CapEx Good for ORCL, HIMS Sells & PFE Rallies on Earnings
Marley Kayden takes investors through the morning's biggest movers, which included Hims & Hers (HIMS) sliding more than 10% after its earnings. Its revenue miss led to the selling action despite the c...
What's Next For HIMS Stock?
Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong growth but did not meet revenue forecasts. The company disclosed revenue of...
Hims & Hers: Buy The Core Engine, Not The Headline
Hims & Hers Health's Q2 revenue miss and decelerating growth triggered a stock drop, but core business ex-GLP-1 remains robust with strong subscriber growth. Profitability is improving, with adjusted ...
Hims & Hers: Buy The Earnings Dip, Slowly (Rating Downgrade)
Despite a Q2 revenue miss and cash flow inflection into negative territory, Hims & Hers' long-term growth prospects remain intact due to ongoing platform broadening and international expansion. Manage...
Hims & Hers Health, Inc. (HIMS) Q2 2025 Earnings Call Transcript
Hims & Hers Health, Inc. (NYSE:HIMS) Q2 2025 Earnings Conference Call August 4, 2025 5:00 PM ET Company Participants Andrew Dudum - Co-Founder, Chairman & CEO Bill Newby - Head of Investor Relations ...
Him & Hers Health report Q2 earnings, missing revenue estimates
CNBC's Brandon Gomez reports on Hims & Hers Health's latest earnings report.
Hims & Hers sees ‘an exciting period of growth,' but stock falls
Shares of Hims & Hers Inc. fell after hours on Monday after the wellness and telehealth platform's third-quarter forecast came up shy of Wall Street's estimates, although the company stuck with its fu...
Hims & Hers stock falls 10% on revenue miss
Hims & Hers Health shares fell in extended trading after the company reported second-quarter results that missed Wall Street's expectations for revenue. Revenue increased 73% year over year to $544.8 ...
Hims and Hers beats quarterly profit on steady subscription growth
Hims and Hers Health beat Wall Street estimates for second-quarter profit on Monday, aided by continued subscription growth and surging volume in the telehealth company's weight-loss business.
Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the second quarte...
Sell HIMS Stock Ahead of Its Earnings?
Hims & Hers Health (NYSE:HIMS) is set to announce its earnings on Monday, August 4, 2025. Historically, HIMS stock has reacted unfavorably to earnings announcements.
Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - HIMS
LOS ANGELES , July 31, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS)...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options